Overview

A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants

Status:
COMPLETED

Trial end date:
2025-04-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Itraconazole